Search Results - "Sabbagh, M.N."

Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021 by Porsteinsson, A. P., Isaacson, R. S., Knox, Sean, Sabbagh, M. N., Rubino, I.

“…Alzheimer’s disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer’s disease progresses along…”
Get full text

Quantitative EEG as a predictive biomarker for Parkinson disease dementia by KLASSEN, B. T, HENTZ, J. G, SHILL, H. A, DRIVER-DUNCKLEY, E, EVIDENTE, V. G. H, SABBAGH, M. N, ADLER, C. H, CAVINESS, J. N

“…We evaluated quantitative EEG (QEEG) measures as predictive biomarkers for the development of dementia in Parkinson disease (PD). Preliminary work shows that…”
Get full text

Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease by Schipke, C G, Peters, O, Heuser, I, Grimmer, T, Sabbagh, M N, Sabri, O, Hock, C, Kunz, M, Kuhlmann, J, Reininger, C, Blankenburg, M

“…Early diagnosis of Alzheimer's disease (AD) may be corroborated by imaging of beta-amyloid plaques using positron emission tomography (PET). Here, we performed…”
Get more information

Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD by Sabbagh, M N, Cooper, K, DeLange, J, Stoehr, J D, Thind, K, Lahti, T, Reisberg, B, Sue, L, Vedders, L, Fleming, S R, Beach, T G

“…Cognitive, global and functional instruments have been extensively investigated for correlations with neuropathological changes such as neurofibrillary tangles…”
Get more information

Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease by Caviness, J.N, Hentz, J.G, Evidente, V.G, Driver-Dunckley, E, Samanta, J, Mahant, P, Connor, D.J, Sabbagh, M.N, Shill, H.A, Adler, C.H

“…Abstract We sought to define quantitative electroencephalographic (EEG) measures as biomarkers of both early and late cognitive decline in Parkinson's disease…”
Get full text

Alzheimer’s Disease Drug Development Pipeline 2020 by Sabbagh, Marwan N.

Get full text

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study by Doraiswamy, P M, Sperling, R A, Johnson, K, Reiman, E M, Wong, T Z, Sabbagh, M N, Sadowsky, C H, Fleisher, A S, Carpenter, A, Joshi, A D, Lu, M, Grundman, M, Mintun, M A, Skovronsky, D M, Pontecorvo, M J

“…This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET),…”
Get full text

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care by Sabbagh, Marwan N., Boada, M., Borson, S., Chilukuri, M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., Hampel, H.

“…Mild cognitive impairment (MCI) is significantly misdiagnosed in the primary care setting due to multi-dimensional frictions and barriers associated with…”
Get full text

Examining the Role of Microbiota in Emotional Behavior: Antibiotic Treatment Exacerbates Anxiety in High Anxiety-Prone Male Rats by Glover, M.E., Cohen, J.L., Singer, J.R., Sabbagh, M.N., Rainville, J.R., Hyland, M.T., Morrow, C.D., Weaver, C.T., Hodes, G.E., Kerman, Ilan A., Clinton, S.M.

“…•Antibiotic treatment increased anxiety-like behavior in rats with innately high, but not low, anxiety-like behavior.•Proliferation of bacteria following…”
Get full text

Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting by Sabbagh, Marwan N., Boada, M., Borson, S., Doraiswamy, P. M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., Hampel, H.

“…Emerging digital tools have the potential to enable a new generation of qualitative and quantitative assessment of cognitive performance. Moreover, the…”
Get full text

Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies by Sabbagh, Marwan N., Boada, M., Borson, S., Chilukuri, M., Doraiswamy, P. M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., Hampel, H.

“…Disease-modifying pharmacotherapies for Alzheimer’s Disease (AD) are currently in late-stage clinical development; once approved, new healthcare…”
Get full text

Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes by CASELLI, R. J, DUECK, A. C, RADEMAKERS, R, FINDLEY, S, REIMAN, E. M, LOCKE, D. E. C, SABBAGH, M. N, AHERN, G. L, RAPCSAK, S. Z, BAXTER, L. C, YAARI, R, WOODRUFF, B. K, HOFFMAN-SNYDER, C

“…To characterize the effects of cerebrovascular (CV) risk factors on preclinical memory decline in cognitively normal individuals at 3 levels of genetic risk…”
Get full text

Cholinergic dysfunction in diseases with Lewy bodies by TIRABOSCHI, P, HANSEN, L. A, ALFORD, M, SABBAGH, M. N, SCHOOS, B, MASLIAH, E, THAL, L. J, COREY-BLOOM, J

“…To evaluate cholinergic activity in diseases with Lewy bodies (LB; LB variant of AD [LBV], diffuse LB disease [DLBD], and Parkinson's disease [PD]) to…”
Get full text

Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease by Arab, L, Sadeghi, R, Walker, D G, Lue, L-F, Sabbagh, M N

“…There is an urgent need for new ways to treat Alzheimers disease (AD), the most common cause of dementia in the elderly. Current therapies are modestly…”
Get full text

Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease by Sabbagh, M N, Lahti, T, Connor, D J, Caviness, J N, Shill, H, Vedders, L, Mahant, P, Samanta, J, Burns, R S, Evidente, V G H, Driver-Dunckley, E, Reisberg, B, Bircea, S, Adler, C H

“…Previously we have shown that functional declines in Parkinson's disease (PD) and Alzheimer's disease (AD) correlate to global measures of cognitive decline…”
Get more information

Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? by Sabbagh, M.N., Silverberg, N., Bircea, S., Majeed, B., Samant, S., Caviness, J.N., Reisberg, B., Adler, C.H.

“…Since many Parkinson’s disease (PD) subjects develop dementia, we determined whether the correlation between functional and cognitive decline seen in…”
Get full text

E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease by COREY-BLOOM, J, TIRABOSCHI, P, HANSEN, L. A, ALFORD, M, SCHOOS, B, SABBAGH, M. N, MASLIAH, E, THAL, L. J

“…To investigate the relationship between apolipoprotein E (APOE) genotype and both cholinergic dysfunction and synapse loss in AD. A reduction in neocortical…”
Get full text